Evommune, Inc. · NYSE:EVMN
Evommune — Investor Presentation (November 2026)
61 slides from Evommune's investor presentation, Nov 12, 2026
Slide 1: Corporate Presentation November 2026
Corporate Presentation November 2026 © Evommune, Inc.
Slide 2: Disclaimers
Disclaimers This presentation has been prepared by Evommune, Inc. (“we”, “us” or “our”) and contains forward-looking statements, including: statements about our expectations regarding the potential benefits, clinical activity and tolerability of our product candidates; our expectations with regard t
Slide 3: Chronic Inflammation is a Global Healthcare Crisis
Chronic Inflammation is a Global Healthcare Crisis © Evommune, Inc. 1. https://www.ncbi.nlm.nih.gov/books/NBK493173/. 2. Wylezinski LS, et al. PMID: 30979036. 3. GlobalData, 2023. 4. GlobalData, 2023 (US/EU5/JP forecasts). Annual Direct Cost2 $90B I&I Therapies Fail Patients >50% Deaths Worldwide1 3
Slide 4: A Broad Portfolio Progressing Multiple Opportunities
A Broad Portfolio Progressing Multiple Opportunities © Evommune, Inc. 1. Moderate-to-severe atopic dermatitis, US adults; Chiesa Fuxench ZC, et al. J Invest Dermatol 2019. 2. US/EU5/JP eligible patients estimated. Sources: Clarivate “Migraine: Disease Landscape and Forecast” (2026), AHS guidelines f
Slide 5: Advancing Multiple Programs Toward Clinical Proof-of-Concept
Advancing Multiple Programs Toward Clinical Proof-of-Concept Program/Target Indication Preclinical Phase 1 Phase 2 Phase 3 EVO301 IL-18BP Atopic Dermatitis Ulcerative Colitis EVO756 MRGPRX2 Migraine EVO570 VAV1 MGD Rheumatoid Arthritis EVO646 TLR7/8 Antagonist Autoimmune Diseases Pipeline of Potenti
Slide 6: Key Milestones Ahead For Evommune
Key Milestones Ahead For Evommune © Evommune, Inc. ~$290m Cash and Investments1, Current Runway Into 2H 2029 Championing Innovation for Chronic Inflammation EVO301 IL-18BP Plan to initiate Phase 2b in AD with subcutaneous formulation in mid-2027 Plan to initiate Phase 2a in UC in 1H 2027 EVO756 MRGP
Slide 7: EVO301: Potential Best-in-Class IL-18BP Fusion Protein
EVO301: Potential Best-in-Class IL-18BP Fusion Protein Long-Acting Serum Albumin-Binding Injectable Therapeutic Fusion Protein Designed to Neutralize IL-18 Signaling © Evommune, Inc.
Slide 8: EVO301 Mechanism of Action
IL-36 IL-33 EVO301 Mechanism of Action © Evommune, Inc. Inflammation Lichenification ITCH IL-17C IL-18 IL-31 Nemluvio EVO301 Camoteskimab TL1A Afimkibart Innate Immunity Macrophage NK Cell Mast Cell Dendritic Cell Basophil Eosinophil ILC2 IL-23 IL-22 IL-17A TH17 Cell IL-12 IFN-γ Approved In Developm
Slide 9: IL-18 Blockade Clinically Validated: Safe, Long-Term & Effective
IL-18 Blockade Clinically Validated: Safe, Long-Term & Effective © Evommune, Inc. Human Data Support Long-Term IL-18 Inhibition IL-18BP Is the Basis of EVO301 Mechanism IL-18BP is the body’s natural IL-18 brake1 Tolerated for years, incl. in children2 Human Genetics No AD, infections or other diseas
Slide 10: EVO301 in Atopic Dermatitis (AD)
EVO301 in Atopic Dermatitis (AD) Neutralizing IL-18 to address the Th2 and non-Th2 inflammation that drives AD © Evommune, Inc.
Slide 11: Proven Playbook, Larger Market: AD Could Reach ~$60B
10 20 30 0 50 60 40 Proven Playbook, Larger Market: AD Could Reach ~$60B © Evommune, Inc. Per Evaluate Pharma (May represent projections and not actual sales); “Year 1” for AD represents 2017 (year of Dupixent launch); “Year 1” for Psoriasis represents 2004 (year of Enbrel launch in plaque psoriasis
Slide 12: EVO301 Has Potential to Command Substantial Market Share in AD Market
EVO301 Has Potential to Command Substantial Market Share in AD Market © Evommune, Inc. Sales from Evaluate Pharma may represent projections (accessed Sept 2026). 1. At maintenance. 2. From ’25-’26. 3. Global atopic dermatitis therapeutics market, projected at $29.5B by 2033 from $15.4B in 2024 (7.5%
Slide 13: EVO301 Has Multi-Billion Dollar Potential
EVO301 Has Multi-Billion Dollar Potential © Evommune, Inc. Source: Evommune 2036 estimates based on Evaluate Pharma (2032), Datamonitor (2033) data ~$100B Market IL-18-Driven Diseases 2L+ Advanced Therapy AD Biologic-experienced / inadequate responders 1L Advanced Therapy AD Initiating advanced syst
Slide 14: EVO301: Long-Acting IL-18 Neutralizer Designed for Tissue Targeting
EVO301: Long-Acting IL-18 Neutralizer Designed for Tissue Targeting SAFA and IL-18BP Fused Via Peptide Linker for Extended Neutralization of IL-18 Activity © Evommune, Inc. SAFA - Anti-Serum Albumin Fab-Associated. HSA - Human Serum Albumin SAFAbody™ is a trademark of AprilBio Co., Ltd. Free IL-18 I
Slide 15: EVO301 Matches Biologics on Th2, Then Goes Beyond It
Therapy Adaptive Inflammation Innate Inflammation Skin Barrier (IL-22) No Conjunctivitis Signal Th2 TH1 TH17 EVO301 DUPIXENT® EBGLYSS® ADBRY® NEMLUVIO® EVO301 Matches Biologics on Th2, Then Goes Beyond It Clinically Validated Modulation of Th2 and Non-Th2 Inflammation © Evommune, Inc. Green = impact
Slide 16: EVO301 Phase 2a Proof-of-Concept Trial Design
EVO301 Phase 2a Proof-of-Concept Trial Design One dose, administered twice © Evommune, Inc. EASI = Eczema Area and Severity Index; vIGA = Validated Investigator Global Assessment; BSA = Body Surface Area; BL = Baseline; PBO = Placebo. Trial identifier: NCT06723405 Adults with Moderate-to-Severe Atop
Slide 17: EVO301 Achieved the Primary Endpoint
EVO301 Achieved the Primary Endpoint Phase 2a Proof-of-Concept Trial in Moderate-to-Severe Atopic Dermatitis (N=70) © Evommune, Inc. 34% placebo-adjusted EASI improvement at week 8 (33% at week 12) 23% of patients achieved vIGA 0/1 at week 12 vs 0% on placebo Highly significant EASI reductions vs pl
Slide 18: Rapid, Robust and Durable Separation from Placebo
Rapid, Robust and Durable Separation from Placebo One dose, administered twice © Evommune, Inc. Week 2 Week 0 Week 4 Week 8 Week 12 % Average Change in EASI * * ↓ % Average change in EASI is LS Mean -22 -18 -16 -22 -30 -41 -50 -55 * ↓ Dosed at Weeks 0 and 4 Placebo (n=22) EVO301 (n=48) *p<0.01 ↓ Off
Slide 19: EVO301 Comparable Activity to Dose-Optimized Marketed Biologics
EVO301 Demonstrated Comparable Activity at 12 Weeks to Dose-Optimized Marketed Biologics at 16 Weeks © Evommune, Inc. IL-18 IL-31 IL-13 IL-4 / IL-13 For illustrative purposes only. Not a head-to-head comparison. Differences exist between trial designs and trial characteristics, and caution should be
Slide 20: EASI-75 Response Continued to Rise After the Last Dose
EASI-75 Response Continued to Rise After the Last Dose Rapid, Durable and Increasing Responses with Just One Dose, Administered Twice © Evommune, Inc. Week 2 Week 0 Week 4 Week 8 Week 12 Patients Achieving EASI-75 EASI-75 = ≥75% improvement in EASI. EVO301 vs placebo: p=0.148 (Wk 8), p=0.069 (Wk 12)
Slide 21: EVO301 Ph2a EASI-75 Matches Lebrikizumab Without TCS
EVO301 Ph2a EASI-75 Matches Lebrikizumab Without TCS Lebrikizumab Dose-Optimization After Ph2a Drove Substantial Improvements in EASI-75 Lebrikizumab Precedent EVO301 matched Lebri's Ph2a efficacy without TCS EVO301 reached 20% with no TCS; Lebri's Ph2a arms reached 5-21%, all with TCS Phase 3 optim
Slide 22: EVO301 Impacts Biomarkers Th2 and Beyond
EVO301 Impacts Biomarkers Th2 and Beyond Matches IL-13 Therapies on Th2, and Impacts Th1 and Th17/22 © Evommune, Inc. 1Th2-high subjects (n=11): TARC ≥ 929 pg/mL, CCL-22 ≥ 2,348 pg/mL; 2Th1-high subjects (n=9): CXCL9 ≥ 56 pg/mL, CXCL10 ≥ 205 pg/mL; 3Th17-high subjects (n=12): S100A12 ≥ 159 pg/mL; 4a
Slide 23: IL-4/13 Co-administration with EVO301 Showed No Additive Benefit in vivo
IL-4/13 Co-administration with EVO301 Showed No Additive Benefit in vivo © Evommune, Inc. Chronic oxazolone-induced atopic dermatitis preclinical model Normal Vehicle anti-IL-4Rα mAb (3 mpk)* EVO301 (3 mpk)* anti-IL-4Rα mAb (3 mpk) + EVO301 (3 mpk)* Mean cumulative score (erythema, scaling, thicknes
Slide 24: EVO301 Subcutaneous Formulation Exposure Consistent with IV
EVO301 Subcutaneous Formulation Exposure Consistent with IV Subcutaneous Formulation Work Complete, Trial Initiation On-Track for Mid-2027 © Evommune, Inc. Comparable Nonclinical Serum Exposure Key PK Parameters Parameters 10mg/kg (N = 3/group) Intravenous (IV) Subcutaneous (SC) Cmax (mg/mL) 343 90
Slide 25: Planned EVO301 Phase 2b Dose-Ranging Trial in AD
Planned EVO301 Phase 2b Dose-Ranging Trial in AD Trial Initiation Expected Mid-2027 © Evommune, Inc. EASI = Eczema Area and Severity Index; vIGA = Validated Investigator Global Assessment; Pruritus-NRS = Pruritus Numerical Rating Scale; BSA = Body Surface Area; BL = Baseline, QoL = Quality of Life;
Slide 26: EVO301 in Inflammatory Bowel Disease
EVO301 in Inflammatory Bowel Disease Extending IL-18BP into ulcerative colitis (UC), where epithelial barrier failure drives disease © Evommune, Inc.
Slide 27: Current Therapies Stall at 20-30% Remission
Current Therapies Stall at 20-30% Remission © Evommune, Inc. 1.25M Americans living with UC1 20-30% Remission rates in induction trials of advanced therapies2 1 in 5 Patients hospitalized within five years of diagnosis3 $6.4B Skyrizi IBD sales in 2025, more than double 20244 1. Lewis JD et al., Gast
Slide 28: UC is a Large and Expanding Market Where Innovation Can Win
UC is a Large and Expanding Market Where Innovation Can Win >$21B by 2033, with Durable Remission Still Out of Reach for Most Patients © Evommune, Inc. >$21B UC therapy sales in 20331 +$10.4B (~92%) market growth expected 3.3M Patients in 7MM2 Multiple Mechanisms Expected to Exceed $1B (2033 project
Slide 29: EVO301 Targets Epithelial Barrier Failure, the First Trigger in IBD
© Evommune, Inc. EVO301 Targets Epithelial Barrier Failure, the First Trigger in IBD Translates to Potential Barrier Repair 29 IL-18 blocks goblet cell and mucus barrier repair2 IL18R1-IL18RAP variants raise IBD risk1 IL-18 elevated in inflamed IBD mucosa1 Preclinical Validation Human Genetics Barri
Slide 30: EVO301 Reversed Established Fibrosis in vivo
EVO301 Reversed Established Fibrosis in vivo A Differentiating Effect Not Observed with Current IBD Therapies © Evommune, Inc. MASH: metabolic dysfunction-associated steatohepatitis. 1 Rieder et al., Gut, 2024;73:854-866. AprilBio 2025, PMID: 40239621, PMID: 27720839 Note: EVO301 vs resmetirom: not
Slide 31: Planned EVO301 Ulcerative Colitis Proof-of-Concept Phase 2a Trial
Planned EVO301 Ulcerative Colitis Proof-of-Concept Phase 2a Trial © Evommune, Inc. UC: ulcerative colitis; mMCS: modified Mayo Clinical Score; PRO: patient reported outcomes; Fcal: fecal calprotectin, hsCRP: high sensitivity C-reactive protein; LRG: Leucine-rich α2-glycoprotein; NGAL: Neutrophil Gel
Slide 32: EVO756: Oral MRGPRX2 Antagonist
EVO756: Oral MRGPRX2 Antagonist Potential First- and Best-in-Class Dual Mechanism Modulates Both Peripheral Sensory Neurons and Mast Cells © Evommune, Inc.
Slide 33: EVO756: Targeting Major Unmet Need in Migraine Prevention
EVO756: Targeting Major Unmet Need in Migraine Prevention © Evommune, Inc. 1. US/EU5/JP eligible patients estimated. Sources: Clarivate “Migraine: Disease Landscape and Forecast” (2026), AHS guidelines for migraine prevention eligibility, Buse et al. (2024), Silberstein et al. (2015), Cohen et al. (
Slide 34: Innovation in Migraine Prevention Has Been Largely Limited to CGRPs
Advanced Treatments Class Route of Admin. MMDs on drug Annual US Sales CGRP Oral QD 12.3 $1.5B Oral EOD * $2B IV 7.9 $1.3B SC 14.6 $0.3B SC *11.2 $0.4B SC 11.3 $0.6B Neuro-toxin IM *11.5 $2B Innovation in Migraine Prevention Has Been Largely Limited to CGRPs © Evommune, Inc. MMD = Monthly Migraine D
Slide 35: High Demand for Preventive Migraine Therapy
High Demand for Preventive Migraine Therapy © Evommune, Inc. Sources: Clarivate “Migraine: Disease Landscape and Forecast” (2026), AHS guidelines for migraine prevention eligibility, Buse et al. (2024), Silberstein et al. (2015), Cohen et al. (2024), Coppola et al. (2025), Sakai et al. (2022). Note:
Slide 36: Strong Scientific Rationale for EVO756 in Migraine
Strong Scientific Rationale for EVO756 in Migraine © Evommune, Inc. MRGPRX2 is expressed in human trigeminal neurons and meningeal mast cells Disease-Relevant Expression in vivo headache models support pathogenic role for MRGPRX2 Preclinical Validation Translational Insights Multiple MRGPRX2 ligands
Slide 37: MRGPRX2: Positioned to Address Neuronal and Mast Cell Drivers of Migraine
MRGPRX2: Positioned to Address Neuronal and Mast Cell Drivers of Migraine © Evommune, Inc. Source: Evommune internal data (trigeminal neurons; in situ hybridization on human tissue samples), PMID: 40712576 (meningeal mast cells) Expression Confirmed in Disease-Relevant Tissues MRGPRX2 nuclei Trigemi
Slide 38: PACAP Inhibition Achieves CGRP-Like Efficacy in Migraine Prophylaxis
PACAP Inhibition Achieves CGRP-Like Efficacy in Migraine Prophylaxis © Evommune, Inc. Note: Lundbeck’s bocunebart is a humanized mAb that neutralizes PACAP. Results above from Phase 2a trial in migraine prophylaxis (HOPE; N=237; single IV administration of bocunebart in patients who were a mix of ep
Slide 39: PACAP Triggers Migraine via MRGPRX2
PACAP Triggers Migraine via MRGPRX21 © Evommune, Inc. 1. Mrgprb2 is rodent homologue. 2. In grams, measured via Orbital von Frey assessment. Source: Internal Evommune data. Confirms data published in PMID: 37516794. Facial withdrawal threshold2 in vivo data support functional role of MRGPRX21 signal
Slide 40: PACAP Impact in Migraine Is Primarily Through MRGPRX2
PACAP Impact in Migraine Is Primarily Through MRGPRX2 © Evommune, Inc. 1. Trigeminal sensory neurons, brainstem pain circuits, hypothalamus, cortex, thalamus. Note: In addition to MRGPRX2, PACAP binds PAC1, VPAC1, VPAC2, but PAC1 inhibition (Amgen’s AMG301: PAC1 blocking mAb) does not show therapeut
Slide 41: Neuropeptides That Trigger Migraine Signal Through MRGPRX2
3 Neuropeptides That Trigger Migraine Signal Through MRGPRX2 © Evommune, Inc. Note that PACAP also binds PAC1, VPAC1, VPAC2, but PAC1 inhibition does not show therapeutic benefit in migraine. PACAP VIP Substance P MRGPRX2
Slide 42: Blocking MRGPRX2 Addresses Validated Migraine Triggers
Neuropeptide Preclinical Evidence Induced Headache in Humans Clinical Validation PACAP VIP Substance P Blocking MRGPRX2 Addresses Validated Migraine Triggers © Evommune, Inc. Note that PACAP also binds PAC1, VPAC1, VPAC2, but PAC1 inhibition does not show therapeutic benefit in migraine.
Slide 43: EVO756 Clinical Development Overview
EVO756 Clinical Development Overview © Evommune, Inc. CIndU = Chronic inducible urticaria; CSU = Chronic Spontaneous Urticaria; AD = Atopic dermatitis Trial Phase 1 Proof-of-Concept Phase 2 Phase 2b N 132 30 ~330 Indication Healthy Volunteers CIndU Migraine Key Takeaways Well-tolerated Clear target
Slide 44: Phase 2b Dose-Ranging Trial in Migraine Prophylaxis
Phase 2b Dose-Ranging Trial in Migraine Prophylaxis Top-line Data Expected in 2H 2027 © Evommune, Inc. BL = Baseline; CFB = change from baseline; MMD = monthly migraine days; MHD = monthly headache days; QoL = quality of life BL Adults with Refractory Migraine ≥6 Days/Month (N ≈ 330) Screening Enrol
Slide 45: EVO570: VAV1 Molecular Glue Degrader
EVO570: VAV1 Molecular Glue Degrader JAK-like Oral Degrader with Potential for Improved Safety and a Best-in-Class Profile in Autoimmune Disease © Evommune, Inc.
Slide 46: VAV1 Could Be the Next Major I&I Class
VAV1 Could Be the Next Major I&I Class JAK-like oral convenience with immune-cell selectivity, starting in RA © Evommune, Inc. JAK Inhibitors Today ~$12.5B4 2025 WW JAK class sales Oral, once-daily dosing Approved in 10+ I&I indications Boxed warning limits most use to 2L How VAV1 Differs Immune-cel
Slide 47: VAV1 Biology Overlaps with Approved I&I Drug Mechanisms
VAV1 Biology Overlaps with Approved I&I Drug Mechanisms Seven drug classes span nine indications; VAV1 has direct evidence in each T-cell mediated T/B-cell mediated Drug class Example drugs Psoriasis UC Crohn’s PsA RA MS MG SLE Sjögren’s Route TNF Humira, Enbrel Inj. IL-17A Taltz, Cosentyx Inj. IL-6
Slide 48: VAV1: JAK-Like with a More Selective Profile
VAV1: JAK-Like with a More Selective Profile © Evommune CONFIDENTIAL VAV1 JAK1 JAK2 JAK3 TYK2 T-cell depletion B-cell depletion (Rituximab) Expression is limited to immune cells Modulates T-cell function Modulates B-cell function Phenotype of KO mouse N/A N/A Modulates cytokine production Immune cel
Slide 49: EVO570 Meets or Exceeds MRT-6160 and Standard of Care
EVO570 Meets or Exceeds MRT-6160 and Standard of Care Across All Tested Disease Models © Evommune CONFIDENTIAL Multiple Sclerosis (MS) Rheumatoid Arthritis (RA) Inflammatory Bowel Disease (IBD) EVO570 previously known as HC118
Slide 50: EVO570 Outperforms MRT-6160 in Preclinical Head-to-Head
EVO570 Outperforms MRT-6160 in Preclinical Head-to-Head ~20× greater degradation potency with clean selectivity and a potential for low dosing © Evommune, Inc. Property MRT-6160 (Novartis) EVO570 EVO570 Advantage VAV1 DC50 (HiBiT, Jurkat) 7 nM 0.3 nM ~20× more potent Max degradation (Dmax) 97% 99% D
Slide 51: Planned China Phase 1 Trial Design
PART A: SAD Dosing 8 Cohorts: Oral dose of EVO570 or pbo (10 per group, 8:2) Planned China Phase 1 Trial Design Will support global Phase 2 program © Evommune, Inc. Cohort A1 (0.1mg) Cohort A8 Cohort A4 Cohort A3 Cohort A2 Cohort B1 Cohort B3 Cohort B2 PART B: MAD Dosing 4 Cohorts: Oral doses of EVO
Slide 52: EVO646: Oral TLR7/8 Antagonist
EVO646: Oral TLR7/8 Antagonist Potential Best-in-Class Dual Mechanism (Type I Interferon and Pathogenic B-Cell / Autoantibody) for Autoimmune Disease © Evommune, Inc.
Slide 53: TLR7/8 Inhibition Suppresses Two Major Drivers of Autoimmune Disease
TLR7/8 Inhibition Suppresses Two Major Drivers of Autoimmune Disease © Evommune, Inc. Type I Interferon Pathway Pathogenic B-Cell Pathway ↓ Type I IFN ↓ Autoantibodies Elevated antibody B cell IL-1β TNFα IL-6 Inflammation IFNα IFNβ pDC Plasma cell Single Target with Complementary Effects on Two Majo
Slide 54: Large Autoimmune Market Opportunity for TLR7/8
Large Autoimmune Market Opportunity for TLR7/8 © Evommune, Inc. Strong Scientific Rationale for TLR7/8 in Autoimmune Diseases Mechanistic Insights Human Genetics Clinical POC Preclinical Validation Strong causal link of TLR7 to autoimmune disease TLR7-/- mice resistant to autoimmune/inflammatory mod
Slide 55: TLR7/8 Inhibition Is Clinically Validated in Lupus
~30-Point SRI-4 Benefit at Every Dose in Phase 2 SLE3,4 TLR7/8 Inhibition Is Clinically Validated in Lupus, with Oral Best-in-Disease Efficacy and Favorable Tolerability in Phase 25 © Evommune, Inc. 1. Enpatoran is an investigational product being developed by EMD Serono. 2. Enpatoran WILLOW Phase 2
Slide 56: EVO646 Targets TLR7/8 and Spares TLR9
EVO646 Targets TLR7/8 and Spares TLR9 Genetics, disease models and two Phase 2 trials all point to TLR7/8 as the productive pair © Evommune, Inc. HUMAN GENETICS TLR7 gain of function causes lupus TLR7 variants drive disease in patients and in mice¹ No comparable gain-of-function case for TLR9 EVO646
Slide 57: EVO646: Selective Interferon and B-Cell Modulator in a Pill
EVO646: Selective Interferon and B-Cell Modulator in a Pill Best-in-class potential EVO646 (Evommune) Afimetoran (BMS/Beeline) Enpatoran (Merck Serono) Potency (nM) (HEK293T) 6.70 1.70 11.2 In vivo activity Mouse PD* >80% inhibition @ 1mpk >80% inhibition @ 1mpk >80% inhibition @ 1mpk Dosing QD QD B
Slide 58: Key Milestones Ahead For Evommune
Key Milestones Ahead For Evommune © Evommune, Inc. ~$290m Cash and Investments1, Current Runway Into 2H 2029 Championing Innovation for Chronic Inflammation EVO301 IL-18BP Plan to initiate Phase 2b in AD with subcutaneous formulation in mid-2027 Plan to initiate Phase 2a in UC in 1H 2027 EVO756 MRGP
Slide 59: Thank You!
Thank You! www.evommune.com © Evommune, Inc.
Slide 60: Appendix
Appendix © Evommune, Inc.
Slide 61: Proven and Experienced Leadership Team
Proven and Experienced Leadership Team Has Delivered Almost 30 NDAs and BLAs © Evommune, Inc. Footnotes: Acquisition prices from press releases Luis Peña Founder, President & CEO Eugene Bauer, MD Founder, CMO Kyle Carver, MBA CFO Greg Moss, Esq. CBO & CLO Jeegar Patel, PhD CSO Janice Drew, MPH Chief